eligibility_summary
Inclusion: Adults ≥18 with progressing, measurable multiple myeloma, ECOG ≤2, 1–3 prior lines including IMiD, proteasome inhibitor, and anti‑CD38, able to consent/comply. Contraception/pregnancy rules, no breastfeeding. Exclusion: non‑MM plasma cell disorders, CNS disease, active serious illness/infection, neuropathy >2, hepatitis B/C, HIV, prior iberdomide/elotuzumab, recent conflicting therapies/surgeries, key lab/organ dysfunction, hypersensitivity, strong CYP3A inhibitors, incarceration.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1 dose‑escalation/expansion trial in relapsed/refractory multiple myeloma testing: 1) Iberdomide (CC‑220): oral CELMoD/IMiD. Mechanism: binds cereblon E3 ligase, drives degradation of IKZF1/IKZF3, yielding direct anti‑myeloma effects and immune stimulation (enhanced T/NK activity, IL‑2). 2) Elotuzumab: IV humanized IgG1 monoclonal antibody against SLAMF7 (CS1). Mechanism: activates NK cells and mediates antibody‑dependent cellular cytotoxicity (ADCC) against SLAMF7+ myeloma cells via Fcγ engagement. 3) Dexamethasone: glucocorticoid, induces plasma‑cell apoptosis, anti‑inflammatory, reduces infusion reactions. Targets/pathways: malignant plasma cells, cereblon–IKZF axis, SLAMF7 on myeloma and NK cells, NK/T‑cell effector function and Fc‑mediated ADCC.